Change in Preferred Drug List Status for "Glucocorticoids, Inhaled" Drug Class Takes Effect Dec. 15

The manufacturer of brand-name Flovent HFA and Flovent Diskus products confirmed they will discontinue these products on Dec. 31, 2023, and some supplies of the products will remain available until early 2024. Due to this discontinuation, HHSC will remove the non-preferred status from the generic fluticasone HFA and Qvar products on the preferred drug list (PDL). The preferred status of brand-name Flovent HFA and Flovent Diskus will not change. This will allow the usage of the existing stock of these medications.

HHSC will remove the non-preferred status for the drugs in the table below, effective Dec. 15. These changes will allow providers to prescribe the generic fluticasone HFA and Qvar products without requiring a PDL prior authorization and continue accessing necessary medication for clients.